Short answer
Prestige Consumer Healthcare Inc. (PBH) filed its Q4 2025 10-Q quarterly report on Feb 5, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $283M (down 2.4% year over year) with net income of $47M.
Q4 2025 key financials · XBRL
- Revenue
- $283M
- −2.4% YoY · +3.4% QoQ
- Net income
- $47M
- −23.5% YoY · +10.6% QoQ
- Operating margin
- 29.1%
- Gross margin
- 55.5%
- EPS (diluted)
- $0.97
- −20.5% YoY · +12.8% QoQ
Source: XBRL data from the Prestige Consumer Healthcare Inc. (PBH) Q4 2025 10-Q on SEC EDGAR. USD.
Prestige Consumer Healthcare Inc. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Acquisition of Pillar5 Pharma in Dec 2025 triggered increased borrowing of $40M under asset-based revolver to partially fund deal
- Most materially updated risk: Supply chain disruptions causing product shortages, especially Eye & Ear Care, negatively impacting sales and operations
- Regulatory/legal risk: Global minimum tax legislation adoption could increase income taxes and affect future tax provisions
- Operational risk: Increased allowance for doubtful accounts on one specific customer raised G&A expenses by $3.5M in Q1 2026
- Financial risk: Total indebtedness of $1.04B including $400M 2028 and $600M 2031 notes, with fixed charge ratio covenant >1.0 maintained at Dec 31, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Prestige Consumer Healthcare Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.